Immunologic Factor
oprelvekin
[ oh-prel-veh-kin ]
Brand Names:
Neumega
Effect:
Increased Megakaryocte Cell Production; Increased Thromboxane Production
May Prevent:
Thrombocytopenia
Definitions related to oprelvekin:
-
A drug used to increase the number of blood cells, especially platelets, in some cancer patients receiving chemotherapy. Neumega is a form of interleukin-11 (a cytokine normally made by support cells in the bone marrow) that is made in the laboratory. It is a type of biological response modifier.NCI Dictionary of Cancer TermsU.S. National Cancer Institute, 2021
-
A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin 11 (IL-11). Secreted by bone marrow stromal cells and a number of mesenchymal cells, IL-11 binds to and activates its cell-surface receptor, promoting primary and secondary immune responses, modulating antigen-specific antibody reactions, and preventing apoptotic cell death. This agent also stimulates the T-cell-dependent development of IgG-secreting B-cells in spleen cell cultures and may be an important regulator of megakaryocytopoiesis. (NCI04)NCI ThesaurusU.S. National Cancer Institute, 2021
Return to OpenMD Medical Dictionary
> O
This content should not be used in place of medically-reviewed decision support reference material or professional medical advice. Some terms may have alternate or updated definitions not reflected in this set. The definitions on this page should not be considered complete or up to date.